Paul Ockelford
Paul has been an Haematologist in Auckland since 1983 working at the School of Medicine, Diagnostic Medlab (now deceased) and Auckland Hospital. Currently he has a part-time appointment within the Department of Haematology, Auckland City Hopsital and undertakes private consulting through the Mercy Specialists Centre, Gilgit Rd, Epsom. He manages a wide rang of haematological disorders, both malignant and non-malignant, and continues a research interest in venous thromboembolic disorders and anticoagulant therapy. Paul is a former chair and board member of the NZMA and a member of a number of haematology societies.
A New Look at Preventing Thromboembolism Concurrent Workshop Sunday, 15 June 2014 Start 8:30am Duration: 55mins Room 7 Start 9:35am Duration: 55mins Room 7 Venous thromboembolism is common. It has different clinical manifestations as dvt (2/3) and pe (1/3). It maybe provoked (60%) or spontaneous. Diagnosis is usually straightforward using clinical (wells’ score) and readily accessible diagnostic tools (ddimer, uss, ctpa). Objective confirmation is essential as is an assessment of clot burden (“big clots are bad clots”). Initial treatment is currently with lmwheparin followed by warfarin. It maybe a short term or a chronic disease and we need to try and predict those requiring longterm therapy. What are the risk factors for a high likelihood of recurrence once treatment is discontinued. The treatment approach is likely to change again with the imminent availability of funded orally active specific coagulation inhibitors. How will these new agents impact on management. There will be no routine monitoring but new considerations such as short half-life, rapid onset of action, use in the elderly, uncertain longterm complications and reversibilty in an emergency.